Viewing nowRomantine Tablets (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.

MFDS item code 201501639 · Approved 2015.03.27 · Insurance code 693201440
Treatment of moderate to severe Alzheimer's disease
This medication is used in the treatment of moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver can periodically confirm that the patient is taking the medicine. Diagnosis should be made in accordance with currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine is administered orally once daily, at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, reach the maintenance dose by increasing the dose by 5mg per week over the first 3 weeks as follows. First week (Day 1~7) Administer 5mg daily for 7 days. Second week (Day 8~14) Administer 10mg daily for 7 days. Third week (Day 15~21) Administer 15mg daily for 7 days. From the fourth week Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Elderly: Based on clinical data, the recommended dose in elderly patients aged 65 years or older is 20mg daily. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg daily in accordance with the standard dose-escalation schedule after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dosage adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Because there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medicine should not be used in patients who are hypersensitive to its components, have severe liver dysfunction, or have severe renal impairment. It should be administered with caution in patients with epilepsy, those with a history of seizures, and individuals who are predisposed to epilepsy, as the risk of adverse effects may increase when combined with certain medications. Close monitoring is also required for patients at risk of factors that increase urinary acidity (pH), those with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension. While taking this medication, adverse effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur; if symptoms worsen, consultation with healthcare professionals should be sought. There may be interactions with other medications, especially when used concurrently with NMDA antagonists, antipsychotics, skeletal muscle relaxants, and anticoagulants, so it is essential to consult with a doctor or pharmacist. Women who are pregnant or of childbearing potential should carefully consider the risks and benefits of using this medication, and breastfeeding women are advised to discontinue breastfeeding if taking this medication. For pediatric and adolescent patients under the age of 18, it is recommended not to use this medication as its safety and efficacy have not been established. In cases of overdose, symptoms of central nervous system distress and gastrointestinal symptoms may occur, so immediate medical attention should be sought for appropriate treatment. This medication may affect a patient's responsiveness, thus caution is advised when driving or operating machinery, and it should be kept out of reach of children. Additionally, transferring the medication to another container can lead to incidents, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, at room temperature between 1 to 30 degrees Celsius. Storing it this way can help maintain its effectiveness for a longer time.
White rectangular film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.